Cerecin is a clinical-stage biotechnology company focused on developing drugs that target the metabolic bases of central nervous system diseases. Cerecin is supported by two multinational partners, Nestlé S.A. (NSRGY), and Wilmar International Limited (F34.SI) as well as leading financial and institutional investors. Cerecin is headquartered in the United States and Singapore with offices in Australia and South Korea. By bringing together the expertise of its global leadership team and highly differentiated drug development programs, Cerecin is becoming a global leader in neurology drug development.